Please login to the form below

Not currently logged in
Email:
Password:

CRVO

This page shows the latest CRVO news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer’s Eylea as first-line BRVO treatment

NICE backs Bayer’s Eylea as first-line BRVO treatment

vein occlusion ( CRVO), diabetic macular oedema ( DMO), and myopic choroidal neovascularisation (mCNV).

Latest news

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics